Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Lantheus Holdings, Inc. LNTH

Healthcare — Drug Manufacturers Specialty & Generic

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
3.31%

Capital & Financial Ratios

Market Cap
6,580.00
Revenue
1,556.31
Net Income
275.31
Free Cash Flow
392.83
Net Debt
(22.25)
Current Ratio
3.06
Debt/Equity
0.44
P/E ratio
23.88
P/S ratio
4.21
P/B ratio
4.99
Past 5Y EPS Growth
40.75%
This Y EPS Growth
(10.95%)
Next Y EPS Growth
18.29%
Next 5Y EPS Growth
8.96%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 713.66 912.81 359.12 593.30
Receivables 284.29 329.44 374.03 354.06
Inventory 64.03 68.03 64.67 57.55
Other 23.84 16.36 102.14 22.15
1,085.82 1,326.63 899.96 1,027.06
2023 2024 2025 Q'26
Payables 41.19 34.56 42.91 48.11
ST’ Debt 0.82 0.97 0.74 0.70
Other — — 22.47 —
187.35 240.53 333.42 335.68
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 377.33 388.18 — —
—
’25 372.76 378.05 384.01 406.79
1,541.61
’24 369.98 394.09 378.73 391.11
1,533.91
’23 300.78 321.70 319.95 354.00
1,296.43
’22 208.88 223.72 239.29 263.17
935.06
’21 92.51 101.06 102.07 129.56
425.21
’20 90.70 66.01 88.54 94.15
339.41
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 125.13 92.20 — —
—
’25 107.56 87.11 105.29 90.18
390.14
’24 127.24 84.72 175.06 157.73
544.75
’23 108.50 (32.27) 116.74 112.29
305.26
’22 10.26 72.60 93.57 105.35
281.78
’21 9.82 25.87 4.34 13.89
53.92
’20 9.41 (2.16) 8.58 0.57
16.40
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 126.90 89.87 — —
—
’25 98.85 79.15 94.67 81.39
354.05
’24 98.97 73.55 159.25 151.13
482.89
’23 99.33 (42.96) 199.96 100.22
356.54
’22 8.87 68.25 87.48 100.63
265.23
’21 23.12 23.21 1.92 9.35
57.60
’20 6.71 (4.41) 4.84 (3.22)
3.92
in millions of $

EPS

Mar Jun Sep Dec Year
’26 1.80 1.11 — —
—
’25 1.02 1.12 0.41 0.82
3.41
’24 1.87 0.88 1.79 (0.17)
4.36
’23 (0.04) 1.33 1.88 1.47
4.65
’22 0.61 0.61 0.86 (1.74)
0.40
’21 0.13 (0.39) (0.20) (0.59)
(1.06)
’20 0.08 (0.16) (0.10) (0.05)
(0.25)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡‡

Recommendation Rating

2.6
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 23.51 47.46 50.20 47.25 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 87.47 100.85 126.89 111.29 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 698 834 808 1,193 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.34 1.55 1.90 1.29 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 935.06 1,296.43 1,533.91 1,541.61 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 62.21% 54.73% 64.43% 61.10% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 26.72 410.94 430.98 313.79 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.86% 31.70% 28.10% 20.35% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.07 326.66 312.44 233.56 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 49.18 64.34 68.92 74.56 — — —
Depreciation
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.65 18.99 22.17 22.84 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.41 4.79 4.52 3.46 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.11 4.47 7.87 5.78 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.24) 0.75 (0.89) (0.53) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.87 5.22 6.98 5.25 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.53 11.95 15.72 16.15 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 68.49 68.27 69.20 67.49 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 123.59 13.20 19.79 19.35 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.71 3.32 4.04 2.91 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.76 5.28 5.69 4.12 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.86 3.21 3.81 3.05 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.62 11.66 12.10 13.28 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 281.78 305.26 544.75 390.14 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.55) 51.28 (61.86) (36.09) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 265.23 356.54 482.89 354.05 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 429.92 898.47 1,086.11 566.55 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 558.07 562.49 566.25 569.42 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 142.41 (151.16) (346.56) 210.30 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 447.15 815.89 1,088.01 1,089.80 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.57% 21.98% 17.21% 11.10% ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.84% 34.28% 38.52% 14.94% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.16% 51.73% 32.82% 21.45% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Lantheus Holdings (LNTH), a radiopharmaceuticals leader, has transformed into a high-growth powerhouse since PYLARIFY’s 2021 FDA approval for prostate cancer imaging, fueling revenue from $339 million in 2020 to $1.53 billion in 2024—a staggering 45% CAGR. This surge reflects explosive market penetration in PSMA-targeted diagnostics, with gross margins expanding to 64.4%, EBT margins at 28.1%, and free cash flow per share reaching $6.98, driving ROIC to 38.5% and a net cash position amid a fortified balance sheet.

Profitability has soared, with net income hitting $312 million in 2024 and EPS at $4.52, supported by operational efficiency (revenue per employee at $1.90 million) and strategic moves like asset sales and theranostics partnerships. However, analyst forecasts show revenue plateauing at $1.50 billion in 2025-2026 before rebounding to $1.71 billion in 2027, tempered by supply constraints and competition.

Recent insider selling totaling $396 million raises caution amid a stock pullback trading 13% below mean targets, yet attractive valuations (EV/Sales at 3.8x, EV/FCF at 12.1x) and pipeline catalysts like LNTH-2401 position LNTH for mid-teens growth in the booming nuclear medicine market—explore the full analysis for risks, milestones, and conviction upside.

Read full commentary →

Lantheus Holdings, Inc. (LNTH) Latest News

News by impact score

Fine-tune

26 Aug

5 pitchbook.com, 4:56 PM
Curium acquires Lantheus Holdings with $5.375B debt financing backing the deal. Acquisition by Curium with $5.375B debt financing fundamentally changes Lantheus ownership structure and long-term trajectory.

14 Aug

4 , 8:00 AM
Lantheus Holdings receives FDA approval for TAUKLARIFY, an F18-labeled tau PET imaging agent for Alzheimer’s disease diagnosis. FDA approval of new Alzheimer’s imaging agent positions Lantheus for major revenue growth and expanded market presence in diagnostics.

6 Aug

4 , 7:24 AM
Lantheus Holdings reported upbeat Q2 CY2026 results. Upbeat quarterly results signal stronger financial performance and improved market positioning.

4 , 7:00 AM
Lantheus Holdings reported its second quarter 2026 financial results. Quarterly earnings directly shape investor views and stock trajectory for Lantheus Holdings.

4 Aug

4 , 12:39 AM
Lantheus Holdings agrees to join Curium in radiopharmaceuticals deal. Partnership with Curium marks major strategic move in radiopharmaceuticals.

3 Aug

5 , 11:28 AM
Lantheus Holdings agrees to an up to $8 billion go-private deal with Curium. The up to $8 billion go-private transaction with Curium will transform Lantheus into a private entity and fundamentally alter its market position and investor dynamics.

5 , 7:38 AM
Curium has announced a definitive agreement to merge with Lantheus Holdings, Inc. (LNTH). Merger agreement with Curium will fundamentally redefine Lantheus Holdings' competitive position and long-term prospects.

27 Jul

4 stocktwits.com, 6:51 PM
LNTH shares fell in after-hours trading after Curium made a $7B acquisition offer below the company's current market value. Curium's below-market $7B bid creates major uncertainty around LNTH ownership and strategic direction.

26 Jun

4 , 4:01 PM
Lantheus Holdings, Inc. received a Complete Response Letter from the FDA for LNTH-2501 (Ga 68 edotreotide). FDA Complete Response Letter delays potential approval of LNTH-2501 and affects Lantheus product pipeline progress.

2 Jun

3 GlobeNewswire, 8:00 AM
Lantheus Holdings' LNTH-2513 (18F-GP1) PET/CT receives SNMMI’s Image of the Year award. Award provides product recognition that may support market positioning without immediate financial or operational shifts.

22 May

4 Simply Wall St., 1:09 PM
Lantheus Holdings faces shifting outlook as PYLARIFY drives revenue growth and pipeline advances reshape competitive positioning and long-term forecasts. PYLARIFY momentum combined with pipeline updates signals major strategic shifts likely to alter revenue trajectory and investor sentiment.

21 May

3 GlobeNewswire, 8:30 AM
Lantheus Holdings presents new radiodiagnostic data at the 2026 SNMMI Annual Meeting, showcasing advancements in nuclear medicine imaging for improved diagnostic capabilities. New data presentation at major industry conference supports product innovation and competitive positioning for Lantheus radiodiagnostics.

14 May

3 , 7:14 AM
Lantheus Holdings (NASDAQ:LNTH) exhibits concerning factors in its earnings, warranting investor awareness. Concerning earnings factors could moderately impact financial performance and market sentiment.

11 May

4 Simply Wall St., 8:04 AM
Lantheus Holdings, Inc. (LNTH) exceeded expectations in its results, leading analysts to update consensus estimates upward. Exceeding expectations and upward consensus estimate revisions signal major positive shifts in financial performance and investor sentiment for LNTH.

8 May

4 transcript www.fool.com, 11:48 AM
Lantheus Holdings (LNTH) released Q1 2026 earnings call transcript detailing quarterly financial results, management commentary, and forward guidance. Q1 2026 earnings transcript reveals financial performance and strategic outlook directly influencing LNTH's stock trajectory and investor sentiment.

4 Zacks Small Cap Research, 5:35 AM
Lantheus Holdings, Inc. (LNTH) reported first quarter 2026 financial and operational results. Quarterly financial results directly shape investor sentiment, stock performance, and future guidance expectations.

4 Simply Wall St., 4:21 AM
Lantheus Holdings (LNTH) valuation reviewed after Q1 earnings beat and FDA approval catalysts. Q1 earnings beat boosts immediate financial sentiment while FDA approvals enable major product expansions and revenue growth.

4 www.marketbeat.com, 2:06 AM
Lantheus Holdings reported Q1 revenue of $338.5 million, up 32% year-over-year and beating estimates, fueled by PYLARIFY sales of $283 million. Diluted EPS reached $1.69, up from $0.68 last year. Net income climbed to $119.4 million. Company raised full-year revenue guidance to $1.425-$1.455 billion from $1.35-$1.39 billion, driven by strong demand and pipeline progress. Earnings beat and raised full-year guidance highlight robust growth and improved market outlook.

7 May

4 StockStory, 7:48 AM
Lantheus Holdings (NASDAQ:LNTH) surprised markets with strong Q1 CY2026 sales, exceeding expectations and highlighting robust performance. Q1 CY2026 sales surprise indicates significant revenue strength, likely driving positive shifts in investor sentiment and stock trajectory.

4 GlobeNewswire, 7:00 AM
Lantheus Holdings, Inc. (LNTH) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates drive significant shifts in investor sentiment and stock performance for LNTH.

10 Apr

3 Simply Wall St., 9:14 AM
Lantheus Holdings (LNTH) valuation faces scrutiny amid cautious investor sentiment driven by expected sales declines and margin pressures. Expected sales declines and margin pressures are poised to moderately affect LNTH's financial performance and market sentiment.

31 Mar

3 Insider Monkey, 11:06 AM
Jefferies raised its price target for Lantheus Holdings (LNTH) from $105 to $110. Jefferies' price target increase reflects positive analyst outlook likely to moderately boost market sentiment and short-term performance.

17 Mar

3 GlobeNewswire, 4:01 PM
Lantheus Holdings announced a three-month extension of the PDUFA date for LNTH-2501 (Ga 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive neuroendocrine tumors. Three-month PDUFA extension delays FDA approval timeline for a key diagnostic imaging product, moderately affecting pipeline progress and market expectations.

12 Mar

4 Simply Wall St., 9:10 PM
Lantheus Holdings (LNTH) stock rose 5.4% after securing dual FDA approvals for radiopharmaceutical expansions in oncology, strengthening its position in a high-growth sector. Dual FDA approvals enable major oncology expansions in radiopharmaceuticals, significantly enhancing LNTH's revenue potential and market position.

3 StockStory, 6:56 AM
Lantheus Holdings (LNTH) merits selling due to three key risks—declining PYLARIFY demand, pipeline delays, and valuation concerns—while one alternative stock offers superior growth prospects. Bearish factors target core revenue drivers and competitive positioning, likely causing moderate pressure on financials and sentiment.

11 Mar

4 StockStory, 10:05 AM
Lantheus Holdings (LNTH) Q4 earnings performance compared to peers in medical devices and supplies imaging diagnostics stocks. Q4 earnings highlights versus sector peers signal significant potential shifts in financial performance and competitive positioning for LNTH.

6 Mar

4 , 4:01 PM
Lantheus Holdings, Inc. announces FDA approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection, an innovative prostate-specific membrane antigen (PSMA) PET imaging agent designed to improve detection of prostate cancer recurrence. FDA approval of PYLARIFY TruVu™ enables a major product launch that strengthens LNTH's leadership in PSMA PET imaging and boosts revenue potential.

2 Mar

4 GlobeNewswire, 8:30 AM
Lantheus Holdings, Inc. received FDA tentative approval for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent to LUTATHERA® for treating neuroendocrine tumors. FDA tentative approval enables potential U.S. market entry for a key radiopharmaceutical, boosting Lantheus' competitive position and revenue prospects.

1 Mar

3 Simply Wall St., 5:06 PM
Lantheus Holdings (LNTH) valuation reassessed after recent share price rebound, focusing on PYLARIFY outlook amid strong demand and growth potential in PSMA-targeted imaging. Share price rebound and PYLARIFY growth outlook signal moderately noticeable influence on financial performance and investor sentiment.

27 Feb

4 app.moby.co, 8:30 AM
Lantheus Holdings, Inc. reported Q4 2025 earnings with revenue of $X million, up Y% year-over-year, EPS of $Z, driven by strong PYLARIFY and DEFENSELYTE sales; full-year 2025 guidance raised, pipeline advancements in radiopharmaceuticals highlighted, shares surged post-call. Q4 earnings beat, raised guidance, and product momentum signal major positive shift in financial trajectory and investor sentiment.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us